Search Result
Results for "
mucosa associated lymphoid tissue lymphoma translocation gene 1
" in MCE Product Catalog:
2826
Inhibitors & Agonists
94
Biochemical Assay Reagents
182
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-P1407
-
|
Z-VRPR-FMK TFA
VRPR
|
MALT1
Influenza Virus
|
Cancer
Infection
|
|
Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection.
|
-
- HY-119695AS
-
|
Simvastatin acid-d6 ammonium
Tenivastatin-d6 (ammonium)
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Simvastatin acid-d6 (ammonium)mis the deuterium labeled Simvastatin acid ammonium. Simvastatin ammonium is an active metabolite of simvastatin lactone mediated by CYP3A4/5 in the intestinal wall and liver (pKa=5.5). Simvastatin ammonium reduces indoxyl sulfate-mediated reactive oxygen species and modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene[1].
|
-
- HY-144001
-
-
- HY-126675A
-
|
AS2863619
|
CDK
STAT
|
Inflammation/Immunology
|
|
AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene.
|
-
- HY-126675
-
|
AS2863619 free base
|
CDK
STAT
|
Inflammation/Immunology
|
|
AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene.
|
-
- HY-132601
-
|
Cobomarsen
MRG-106
|
MicroRNA
|
Cancer
|
|
Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma.
|
-
- HY-P1258A
-
|
PSI TFA
Proteasome Inhibitor 1 TFA
|
Proteasome
|
Cancer
Infection
|
|
PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas.
|
-
- HY-P1258
-
|
PSI
Proteasome Inhibitor 1
|
Proteasome
|
Cancer
Infection
|
|
PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas.
|
-
- HY-119098
-
|
GSK983
|
EBV
HPV
|
Infection
|
|
GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by
EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes.
|
-
- HY-W145518
-
|
Pectin
|
Endogenous Metabolite
Bacterial
Antibiotic
|
Infection
|
|
Pectin is a heteropolysaccharide, derived from the cell wall of higher plants. Pectin involves in the formation of nanoparticles as a delivery vehicle of agents. Pectin is also an adsorbent, a broad-spectrum antimicrobial agent that binds to bacteria toxins and other irritants in the intestinal mucosa, relieves irritated mucosa.
|
-
- HY-111101
-
|
AZ1495
|
IRAK
|
Cancer
|
|
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL).
|
-
- HY-A0261
-
|
Pentagastrin
ICI-50123
|
Cholecystokinin Receptor
|
Cancer
Endocrinology
|
|
Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury..
|
-
- HY-A0261A
-
|
Pentagastrin meglumine
ICI-50123 meglumine
|
Cholecystokinin Receptor
|
Cancer
Endocrinology
|
|
Pentagastrin (ICI-50123) meglumine is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin meglumine enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury..
|
-
- HY-147090
-
-
- HY-N1022
-
|
11-Hydroxytephrosin
|
NF-κB
|
Cancer
Inflammation/Immunology
|
|
11-Hydroxytephrosin is a potent inhibitor of NF-kappaB. NF-kappaB is known to play a crucial role in the regulation of genes controlling the immune system, apoptosis, tumor cell growth, and tissue differentiation.
|
-
- HY-109029
-
|
Dezapelisib
INCB040093
|
PI3K
|
Cancer
|
|
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas.
|
-
- HY-109108
-
|
Valemetostat
DS-3201
|
Histone Methyltransferase
|
Cancer
|
|
Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma.
|
-
- HY-148420
-
|
CDN-A
|
STING
|
Inflammation/Immunology
|
|
CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes.
|
-
- HY-124500
-
|
AC-4-130
|
STAT
Apoptosis
|
Cancer
|
|
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML).
|
-
- HY-D0220
-
|
Toluidine Blue
Toluidine Blue O
|
Fluorescent Dye
|
Cancer
|
|
Toluidine Blue is a basic thiazine metachromatic dye with high affinity for acidic tissue components. Toluidine Blue has wide applications in vital staining in living tissues and a special stain.
|
-
- HY-W008956
-
|
Myoseverin
|
Microtubule/Tubulin
|
Inflammation/Immunology
|
|
Myoseverina, a microtubule-binding molecule, induces the reversible fission of multinucleated myotubes into mononucleated fragments. Myoseverina affects the expression of a variety of growth factor, immunomodulatory, extracellular matrix-remodeling, and stress response genes, consistent with the activation of pathways involved in wound healing and tissue regeneration.
|
-
- HY-P99483
-
|
Blontuvetmab
AT 004; VT 007
|
CD20
|
Cancer
|
|
Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma.
|
-
- HY-P99501
-
|
Zuberitamab
HS006
|
CD20
|
Cancer
|
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.
|
-
- HY-W250110
-
|
Polyethylenimine
|
Biochemical Assay Reagents
|
Cancer
|
|
Polyethylenimine is a class of cationic polymers, is effective for gene delivery. Polyethylenimine is nondegradable and the molecular weight of PEI affects the cytotoxicity and gene transfer activity. Polyethylenimine acts as a low toxicity and efficient gene vector.
|
-
- HY-147091
-
-
- HY-144288
-
|
BLK-IN-2
|
Btk
|
Cancer
|
|
BLK-IN-2 (compound 25) is a potent and selective irreversible inhibitor of B-Lymphoid tyrosine kinase (BLK), with an IC50 of 5.9 nM. BLK-IN-2 also inhibits BTK (IC50=202.0 nM). BLK-IN-2 shows potent antiproliferative activities against several lymphoma cells.
|
-
- HY-16950
-
|
4-Hydroxytamoxifen
(Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene
|
Estrogen Receptor/ERR
|
Cancer
|
|
4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) induces CRISPR/Cas9 systems based on ER mediated nucleus translocation.
|
-
- HY-P1913
-
-
- HY-126621
-
|
DC-TEADin02
|
YAP
|
Cancer
|
|
DC-TEADin02 is a potent TEAD autopalmitoylation inhibitor. DC-TEADin02 has TEAD autopalmitoylation inhibitory with the IC50 value of 197 nM. DC-TEADin02 can be used for the research of development, regeneration and tissue homeostasis.
|
-
- HY-Z0031
-
-
- HY-P99233
-
|
Camidanlumab
HuMax-TAC
|
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia.
|
-
- HY-15614A
-
|
SC144 hydrochloride
|
Interleukin Related
Apoptosis
|
Cancer
|
|
SC144 hydrochloride is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 hydrochloride binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 hydrochloride shows potent inhibition of gp130 ligand-triggered signaling. SC144 hydrochloride induces apoptosis in human ovarian cancer cells.
|
-
- HY-15614
-
|
SC144
|
Interleukin Related
Apoptosis
|
Cancer
|
|
SC144 is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 shows potent inhibition of gp130 ligand-triggered signaling. SC144 induces apoptosis in human ovarian cancer cells.
|
-
- HY-P1913A
-
-
- HY-148335
-
-
- HY-13599
-
|
Cladribine
2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA
|
Adenosine Deaminase
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.
|
-
- HY-14452
-
|
Fatostatin
125B11
|
Fatty Acid Synthase (FASN)
|
Cancer
|
|
Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
|
-
- HY-P3342
-
-
- HY-N7057
-
|
Nonanoic acid
Pelargonic acid; Pelargonic acid (n-Nonanoic acid, C9 )
|
Bacterial
|
Infection
|
|
Nonanoic acid is a naturally-occurring saturated fatty acid with nine carbon atoms. Nonanoic acid significantly reduces bacterial translocation, enhances antibacterial activity, and remarkably increases the secretion of porcine β-defensins 1 (pBD-1) and pBD-2.
|
-
- HY-14171S
-
|
Bexarotene-d4
LGD1069 d4
|
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].
|
-
- HY-N6901
-
|
Luteolin 7-sulfate
|
Epigenetic Reader Domain
|
Metabolic Disease
|
|
Luteolin 7-sulfate is isolated from Phyllospadix iwatensis Makino, a marine plant. Luteolin 7-sulfate attenuates TYR gene expression through the intervention of a cAMP-responsive element binding protein (CREB)- and microphthalmia-associated transcription factor (MITF)-mediated signaling pathway, leading to the decreased melanin synthesis.
|
-
- HY-P99293
-
|
Galiximab
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
|
Cancer
|
|
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma.
|
-
- HY-113130
-
-
- HY-129226
-
|
SHMT-IN-2
|
Others
|
Cancer
Endocrinology
|
|
SHMT-IN-2 is a stereo specific inhibitor of human SHMT1/2 with IC50 values of 13 nM and 66 nM for SHMT1 and SHMT2, respectively. SHMT-IN-2 can block the growth of many human cancer cells, and has sensitivity for B-cell lymphomas.
|
-
- HY-131246
-
|
DM-01
|
Histone Methyltransferase
|
Cancer
|
|
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors.
|
-
- HY-N6684
-
|
Deoxynivalenol
|
Others
|
Metabolic Disease
|
|
Deoxynivalenol, a mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors.
|
-
- HY-151393
-
|
Tubulin polymerization-IN-32
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-32 inhibits cancer cell proliferation. Tubulin polymerization-IN-32 can be used in the research of cancers like lymphomas.
|
-
- HY-146197
-
|
Apoptotic agent-1
|
Apoptosis
|
Cancer
|
|
Apoptotic agent-1 (Compound 8a) is an apoptotic agent with high antiproliferative activity against cancer cells and low cytotoxic effect. Apoptotic agent-1 induces over-expression of Fas receptor and Cyto C genes.
|
-
- HY-14452A
-
|
Fatostatin hydrobromide
125B11 hydrobromide
|
Fatty Acid Synthase (FASN)
|
Cancer
|
|
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
|
-
- HY-P3689
-
-
- HY-P99107
-
|
Brentuximab vedotin
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
TNF Receptor
|
Cancer
|
|
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
|
-
- HY-110258
-
|
ML334
LH601A
|
Keap1-Nrf2
|
Cancer
|
|
ML334 is a potent, cell permeable activator of NRF2 by inhibition of Keap1-NRF2 protein-protein interaction. ML334 binds to Keap1 Kelch domain with a Kd of 1 μM. ML334 stimulates NRF2 expression and nuclear translocation and induces antioxidant response elements (ARE) activity.
|
-
- HY-N1534
-
|
Ponasterone A
25-Deoxyecdysterone
|
Others
|
Others
|
|
Ponasterone A (25-Deoxyecdysterone), an ecdysteroid, has strong affinity for the ecdysone receptor. Ponasterone A is a potent regulator of gene expression in cells and transgenic animals, enabling reporter genes to be turned on and off rapidly.
|
-
- HY-N8102
-
-
- HY-108638
-
|
NSC 146109 hydrochloride
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
NSC 146109 hydrochloride is a small-molecule p53 activator that target MDMX and can be used for breast cancer research. NSC 146109 hydrochloride is a pseudourea derivative, promotes breast cancer cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes.
|
-
- HY-152963
-
|
Tisotumab vedotin
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF). Tisotumab vedotin consists of a fully human monoclonal antibody to tissue factor (TF-011) conjugated to Monomethyl Auristatin E (MMAE). Tisotumab vedotin has good antitumor activity and can be used in the research of advanced or metastatic solid tumors.
|
-
- HY-P99056
-
|
Utomilumab
PF 05082566
|
TNF Receptor
|
Cancer
Inflammation/Immunology
|
|
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 + non-Hodgkin lymphomas (NHL).
|
-
- HY-112391
-
|
SD-1029
|
JAK
STAT
|
Cancer
|
|
SD-1029 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.
|
-
- HY-N2893
-
|
Cepharanone B
Aristolactam B II
|
Others
|
Others
|
|
Cepharanone B is a fluorescent component isolated from the callus tissue of stephania cephaiuntha.
|
-
- HY-142995
-
-
- HY-145261
-
|
hDHODH-IN-8
|
Lactate Dehydrogenase
|
Inflammation/Immunology
|
|
hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma.
|
-
- HY-151398
-
|
Tubulin polymerization-IN-37
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-37 is a tubulin polymerization inhibitor (IC50: 2.3 μΜ). Tubulin polymerization-IN-37 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-37 can be used in the research of cancers, such as lymphomas.
|
-
- HY-146237
-
|
Golcadomide
CC-99282
|
Ligands for E3 Ligase
Molecular Glues
|
Cancer
|
|
Golcadomide (CC-99282) is a potent and orally active cereblon (CRBN) E3 ligase modulator (CELMoD). Golcadomide co-opts CRBN to induce potent and targeted degradation of Ikaros and Aiolos. Golcadomide can be used for researching non-Hodgkin lymphomas.
|
-
- HY-151397
-
|
Tubulin polymerization-IN-36
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-36 is a tubulin polymerization inhibitor (IC50: 2.8 μΜ). Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-36 can be used in the research of cancers, such as lymphomas.
|
-
- HY-N1830
-
|
3-Epiwilsonine
|
Others
|
Cancer
|
|
3-Epiwilsonine is an alkaloid from Cephalotaxus wilsoniana, exhibits effect on acute and chronic myeloid leukemia and malignant lymphoma.
|
-
- HY-133121
-
|
WDR5-IN-1
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
WDR5-IN-1 is a potent and selective WD repeat domain 5 (WDR5) inhibitor, with a Kd of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC50 of 2.2 nM. WDR5-IN-1 diminishes MYC recruitment at WDR5-displaced genes and exhibits potent anti-proliferative effects in CHP-134 (neuroblastoma) and Ramos (Burkitt’s lymphoma) lines.
|
-
- HY-19990
-
-
- HY-125276
-
|
TH5487
|
Others
|
Inflammation/Immunology
|
|
TH5487 is a potent 8-oxoguanine DNA glycosylase 1 (OGG1) inhibitor with an IC50 of 342 nM. TH5487 stops OGG1 from recognizing its DNA substrate, inhibits DNA repair and modifies OGG1 chromatin dynamics, which results in the inhibition of proinflammatory pathway genes.
|
-
- HY-W048303
-
|
L-Azatyrosine
|
Antibiotic
|
Cancer
Infection
|
|
L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes.
|
-
- HY-11028
-
|
PF-02413873
PF-2413873
|
Progesterone Receptor
|
Endocrinology
|
|
PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a Ki of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo.
|
-
- HY-147088
-
|
TEAD-IN-2
|
YAP
|
Cancer
|
|
TEAD-IN-2 is a novel, orally active inhibitor of transcriptional enhancer associate domain (TEAD) and modulates TEAD by ubiquitination and/or degradation by compounds. TEAD-IN-2 can be used for the research of a variety of diseases, disorders or conditions associated with TEAD.
|
-
- HY-B1599
-
|
Chloramphenicol palmitate
|
Bacterial
Antibiotic
|
Infection
|
|
Chloramphenicol palmitate is an orally active broad spectrum antibiotic and has a broad spectrum of activity against gram positive and gram negative bacteria. Chloramphenicol palmitate inhibits bacterial protein synthesis by blocking the peptidyl transferase step. Chloramphenicol palmitate can be used as bacterial selection agent in transformed cells containing chloramphenicol resistance genes.
|
-
- HY-P99258
-
|
Brontictuzumab
OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody
|
Notch
|
Cancer
|
|
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.
|
-
- HY-W012159
-
|
Methionylserine
H-MET-SER-OH
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Methionylserine (H-MET-SER-OH) is a methionine- and serine-containing dipeptide. Methionylserine binds to and translocation via intestinal di/tri-peptide transporter 1 (hPEPT1) with a Km value of 0.2 mM. Methionylserine inhibits ACE enzyme activity. Methionylserine can be used in the research of hypension.
|
-
- HY-123854
-
-
- HY-147413
-
|
Unecritinib
TQ-B3101
|
EGFR
|
Cancer
|
|
Unecritinib (TQ-B3101) is a potent EGFR tyrosine kinase inhibitor. Unecritinib shows anticancer activity. Unecritinib inhibits ALK, ROS1, and MET. Unecritinib has the potential for the research of solid tumor and relapsed or refractory ALK-positive anaplastic large cell lymphoma.
|
-
- HY-124040
-
|
BI-1950
|
Integrin
|
Inflammation/Immunology
|
|
BI-1950 is a highly potent lymphocyte function associated antigen-1 (LFA-1) inhibitor. LFA-1 is an essential component in normal immune system function and a target for agent discovery.
|
-
- HY-109855
-
-
- HY-N9686
-
-
- HY-N2534
-
|
Karanjin
|
AMPK
Apoptosis
|
Cancer
|
|
Karanjin is a major active furanoflavonol constituent of Fordia cauliflora. Karanjin induces GLUT4 translocation in skeletal muscle cells by increasing AMPK activity. Karanjin can induce cancer cell death through cell cycle arrest and enhance apoptosis.
|
-
- HY-133897
-
-
- HY-150019
-
|
PI3K-IN-36
|
PI3K
|
Cancer
|
|
PI3K-IN-36 (compound A36) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL).
|
-
- HY-N4126
-
|
6-Demethoxytangeretin
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
Inflammation/Immunology
Neurological Disease
|
|
6-Demethoxytangeretin is a citrus flavonoid isolated from Citrus reticulata. 6-Demethoxytangeretin exerts anti-inflammatory activity and anti-allergic activity, suppresses production and gene expression of interleukin-6 in human mast cell-1 via anaplastic lymphoma kinase (ALK) and mitogen-activated protein kinase (MAPK) pathways. 6-Demethoxytangeretin facilitates the CRE-mediated transcription associated with learning and memory in cultured hippocampal neurons.
|
-
- HY-P0181
-
-
- HY-P99109
-
|
Zimberelimab
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab is a fully human IgG4 anti-PD-1 monoclonal antibody with high affinity and selectivity. Zimberelimab shows antitumor activities and can be used for various cancers research including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma.
|
-
- HY-15489
-
|
Scriptaid
Scriptide; GCK1026
|
HDAC
Autophagy
Apoptosis
Influenza Virus
|
Cancer
|
|
Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.
|
-
- HY-112292A
-
|
GW806742X hydrochloride
|
Mixed Lineage Kinase
VEGFR
|
Cancer
|
|
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.
|
-
- HY-112292
-
|
GW806742X
|
Mixed Lineage Kinase
VEGFR
|
Others
|
|
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X has activity against VEGFR2 (IC50=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis.
|
-
- HY-145973A
-
|
3'Ome-m7GpppAmpG ammonium
|
DNA/RNA Synthesis
|
Others
|
|
3'Ome-m7GpppAmpG ammonium is a trinucleotide Cap analogue containing a locked nucleic acid (LNA) molecule. 3'Ome-m7GpppAmpG ammonium shows a significant translational efficiency. 3'Ome-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization.
|
-
- HY-W017443
-
-
- HY-19333
-
|
OG-L002
|
Histone Demethylase
Monoamine Oxidase
HSV
|
Infection
|
|
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.
|
-
- HY-N2682A
-
-
- HY-P99619
-
|
Finotonlimab
SCT-I10A
|
PD-1/PD-L1
|
Cancer
|
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research.
|
-
- HY-151395
-
-
- HY-151396
-
-
- HY-P99289
-
|
Epratuzumab
Antibody hLL 2; Anti-Human CD22 Recombinant Antibody
|
CD22
|
Cancer
Inflammation/Immunology
|
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.
|
-
- HY-19836
-
|
Zimlovisertib
PF-06650833
|
IRAK
|
Inflammation/Immunology
|
|
Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas.
|
-
- HY-101566A
-
|
Elimusertib hydrochloride
BAY 1895344 hydrochloride
|
ATM/ATR
|
Cancer
|
|
Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib hydrochloride has anti-tumor activity. Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas.
|
-
- HY-101566
-
|
Elimusertib
BAY 1895344
|
ATM/ATR
|
Cancer
|
|
Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity. Elimusertib can be used for the research of solid tumors and lymphomas.
|
-
- HY-148853
-
|
SRI-42127
|
Interleukin Related
|
Others
|
|
SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes.
|
-
- HY-P99264
-
|
Inotuzumab
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
|
-
- HY-148683
-
|
EG-011
|
Arp2/3 Complex
|
Cancer
|
|
EG-011 is the first-in-class and potent Wiskott-Aldrich syndrome protein (WASP) activator. EG-011 activates the auto-inhibited form of WASP with strong actin polymerization. EG-011 has selective anti-tumor activity in lymphomas.
|
-
- HY-145762
-
|
YM281
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
|
YM281 is a potent EZH2 inhibitor. YM281 induces cell apoptosis and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma.
|
-
- HY-P99952
-
|
Ripertamab
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).
|
-
- HY-148026
-
|
Sonrotoclax
BGB 11417
|
Bcl-2 Family
|
Cancer
|
|
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.
|
-
- HY-106688A
-
-
- HY-W011303
-
-
- HY-P3606
-
|
GnRH Associated Peptide (1-24), human
GAP (1-24), human
|
GnRH Receptor
|
Endocrinology
|
|
GnRH Associated Peptide (GAP) (1-24), human is the human gonadotropin-releasing hormone-associated peptide (GAP) 1-24 fragment (hGAP-1-24). GAP is joined to the luteinizing hormone-releasing hormone (LH-RH) sequence by a 3 amino acid processing site.
|
-
- HY-W009731
-
|
Dibenzoylmethane
|
Keap1-Nrf2
|
Cancer
Metabolic Disease
|
|
Dibenzoylmethane, a minor ingredient in licorice, activates Nrf2 and prevents various cancers and oxidative damage. Dibenzoylmethane, an analog of curcumin, results in dissociation from Keap1 and nuclear translocation of Nrf2.
|
-
- HY-143688
-
|
EDMPC
|
Liposome
|
Others
|
|
EDMPC, a cationic lipid, has an enhanced ability to deliver DNA to pulmonary tissues. EDMPC mediates intralobar DNA delivery to rodents.
|
-
- HY-136390
-
|
ML417
|
Dopamine Receptor
|
Neurological Disease
|
|
ML417 is a selective and brain penetrant D3 dopamine receptor (D3R) agonist, with an EC50 of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons.
|
-
- HY-117658
-
|
GSK-114
|
Others
|
Cardiovascular Disease
|
|
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 µM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue.
|
-
- HY-P1440
-
-
- HY-120231
-
|
Z-VRPR-FMK
|
MALT1
|
Cancer
|
|
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression.
|
-
- HY-P99253
-
|
Mogamulizumab
KW-0761
|
CCR
|
Cancer
Inflammation/Immunology
|
|
Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).
|
-
- HY-P99349
-
|
Loncastuximab tesirine
Loncastuximab tesirine-lpyl; ADCT-402
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma.
|
-
- HY-139200
-
|
DOTMA
|
Liposome
|
Others
|
|
DOTMA, as a tetra-methylated DOTA analogue, is a cationic lipid and can be used as a non-viral vector for gene therapy. It has been used as a component in liposomes that can be used to encapsulate siRNA, microRNAs, and oligonucleotides and for gene transfection in vitro. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome- cell membrane interaction.
|
-
- HY-U00193
-
|
Ro18-5362
|
Others
|
Metabolic Disease
|
|
Ro18-5362 is the less active proagent of Ro 18-5364. Even at concentrations as high as 0.1 mM Ro 18-5362 fails to affect significantly (H ++K +)-ATPase activity and associated proton translocation.
|
-
- HY-P3160
-
|
Fibronectin
|
Integrin
|
Inflammation/Immunology
Cardiovascular Disease
|
|
Fibronectin, a glycoprotein (~500 kDa) present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans.
|
-
- HY-144858
-
|
EZM0414
|
Histone Methyltransferase
|
Cancer
|
|
EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma.
|
-
- HY-50055
-
|
EtDO-P4
|
Others
|
Cancer
|
|
EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma.
|
-
- HY-139308
-
|
T0467
|
Mitochondrial Metabolism
|
Neurological Disease
|
|
T0467 activates parkin mitochondrial translocation in a PINK1-dependent manner in vitro. T0467 do not induce mitochondrial accumulation of PINK1in dopaminergic neurons. T0467 is a potential compound for PINK1-Parkin signaling activation, and can be used for parkinson's disease and related disorders research.
|
-
- HY-138843
-
-
- HY-145692
-
|
Cas9-IN-3
|
CRISPR/Cas9
|
Others
|
|
Cas9-IN-3 is a potent Cas9 inhibitor (IC50=28 μM). CRISPR/Cas systems have revolutionized gene editing in various species.
|
-
- HY-17488
-
|
Morniflumate
UP 164
|
Others
|
Inflammation/Immunology
|
|
Morniflumate (UP 164) is an orally active nonsteroidal anti-inflammatory agent. Morniflumate can be used in the study of inflammatory diseases such as osteoarthritis, painful musculoskeletal disorders and soft tissue inflammation.
|
-
- HY-101872A
-
|
GSK-872 hydrochloride
|
RIP kinase
|
Inflammation/Immunology
|
|
GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.
|
-
- HY-101872
-
|
GSK-872
|
RIP kinase
|
Inflammation/Immunology
|
|
GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.
|
-
- HY-146183
-
|
BCL6-IN-9
|
Bcl-2 Family
|
Cancer
|
|
BCL6-IN-9 (compound 1) is a potent B-cell lymphoma 6 protein (BCL6) inhibitor, with an IC50 of 3.9 nM. BCL6-IN-9 can be used for the research of cancer.
|
-
- HY-148765
-
|
CLK8
|
Cryptochrome
|
Cancer
Metabolic Disease
|
|
CLK8 is a potent and specific CLOCK inhibitor that can disrupt the interaction between CLOCK and BMAL1 and interfere with nuclear translocation of CLOCK. CLK8 can be used for the research of disorders associated with dampened circadian rhythms.
|
-
- HY-12023
-
|
GTx-007
S-4
|
Androgen Receptor
|
Cancer
|
|
GTx-007 (S-4) is an orally active and selective nonsteroidal androgen receptor (AR) modulator (SARM) and a partial agonist, with Ki of 4 nM. GTx-007 (S-4) is identified as SARMs with potent and tissue-selective in vivo pharmacological activity.
|
-
- HY-138843A
-
-
- HY-130994
-
|
Aeruginosin 865
|
NF-κB
ADC Cytotoxin
|
Cancer
Inflammation/Immunology
|
|
Aeruginosin 865, isolated from terrestrial cyanobacterium Nostoc sp. Lukešová 30/93, is the first aeruginosin-type peptide containing both a fatty acid and a carbohydrate moiety. Aeruginosin 865 inhibits translocation of NF-kB to the nucleus. Aeruginosin 865 has anti-inflammatory effect
|
-
- HY-44062
-
|
G9a-IN-1
|
Histone Methyltransferase
|
Inflammation/Immunology
Cancer
|
|
G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer.
|
-
- HY-134094
-
|
Fluridone
|
Others
|
Others
|
|
Fluridone is an inhibitor of abscisic acid (ABA) biosynthesis. Fluridone suppresses the expression of AchnFAR and TF genes and reduces the formation of primary alcohols.
|
-
- HY-135646
-
|
Eleutheroside B1
|
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human influenza virus efficacy, with an IC50 value of 64-125 µg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti-inflammatory activities.
|
-
- HY-P99024
-
|
Glofitamab
RO7082859
|
CD20
|
Cancer
|
|
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.
|
-
- HY-150593
-
|
IRAK4-IN-16
|
IRAK
|
Cancer
|
|
IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC50 of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC50 values of 0.2, 0.2, 0.6, and 2.7 μM, respectively.
|
-
- HY-P0316
-
|
TP508
|
Thrombin
NO Synthase
|
Cardiovascular Disease
|
|
TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues.
|
-
- HY-D1609
-
-
- HY-135732
-
|
SK33
|
Androgen Receptor
|
Cancer
|
|
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity.
|
-
- HY-143653
-
|
BCL6-IN-6
|
Others
|
Cancer
|
|
BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL).
|
-
- HY-150205
-
|
Succinate/succinate receptor antagonist 1
|
Others
|
Inflammation/Immunology
|
|
Succinate/succinate receptor antagonist 1 (compound 7a) is a succinate/succinate receptor antagonist. Succinate/succinate receptor antagonist 1 blocks succinate signaling in gingival tissue. Succinate/succinate receptor antagonist 1 inhibits the activation of succinate receptor 1 (SucnRl) with an IC50 value of 20 μΜ. Succinate/succinate receptor antagonist 1 can be used for the research of periodontal disease.
|
-
- HY-W250978
-
|
Ovalbumins
|
Endogenous Metabolite
|
Cancer
Inflammation/Immunology
|
|
Ovalbumins, the main protein found in egg whites, have various biological activities such as anticancer, antihypertensive, antibacterial, antioxidant and immunomodulatory activities. Ovalbumins are the most abundant proteins synthesized in progesterone- or estrogen-treated fallopian tubes and are commonly used as markers to study hormone control of gene expression in this tissue.
|
-
- HY-138937
-
|
NDB
|
FXR
|
Metabolic Disease
|
|
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research.
|
-
- HY-P3605
-
|
GnRH Associated Peptide (25-53), human
GAP (25-53), human
|
GnRH Receptor
|
Endocrinology
|
|
GnRH Associated Peptide (GAP) (25-53), human is the human gonadotropin-releasing hormone-associated peptide (GAP) 25-53 fragment (hGAP-25-53), can be used as immunogen to generate antiseras including MC-1, MC-2, and MC-3. GAP is joined to the luteinizing hormone-releasing hormone (LH-RH) sequence by a 3 amino acid processing site.
|
-
- HY-153320
-
|
AZ-TAK1
|
MAP3K
|
Cancer
|
|
AZ-TAK1, an ATP-competitive small molecule inhibitor of TAK1, dephosphorylates TAK1, p38, and IκB-α in lymphoma cell lines.
|
-
- HY-44432
-
-
- HY-P0316A
-
|
TP508 TFA
|
Thrombin
NO Synthase
|
Cardiovascular Disease
|
|
TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues.
|
-
- HY-132253
-
|
Polatuzumab vedotin
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
|
-
- HY-N8160
-
|
Dehydrocurdione
|
Keap1-Nrf2
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Dehydrocurdione, a zedoary-derived sesquiterpene, induces heme oxygenase (HO)-1, an antioxidative enzyme, in RAW 264.7 macrophages. Dehydrocurdione interacts with Keap1, resulting in Nrf2 translocation followed by activation of the HO-1 E2 enhancer. Dehydrocurdione suppresses lipopolysaccharide-induced NO release, a marker of inflammation. Anti-inflammatory activity.
|
-
- HY-138683
-
|
STING-IN-3
|
STING
|
Inflammation/Immunology
|
|
STING-IN-3 is an inhibitor of stimulator of interferon genes (STING). STING-IN-3 efficiently inhibits both hsSTING and mmSTING through covalently target the predicted transmembrane cysteine residue 91 and thereby block the activation-induced palmitoylation of STING.
|
-
- HY-141432
-
|
Cbl-b-IN-3
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Cbl-b-IN-3 (Compound 23) is a casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC50 of < 1 nM. Cbl-b is an E3 ubiquitin ligase that negatively regulates T-cell activation.
|
-
- HY-P2217
-
|
Aclerastide
DSC-127; NorLeu3-A(1-7)
|
Angiotensin Receptor
|
Inflammation/Immunology
|
|
Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensin II. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers.
|
-
- HY-143741
-
|
RAD51-IN-7
|
RAD51
|
Cancer
|
|
RAD51-IN-7 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-7 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 71).
|
-
- HY-143736
-
|
RAD51-IN-5
|
RAD51
|
Cancer
|
|
RAD51-IN-5 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-5 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 3).
|
-
- HY-143737
-
|
RAD51-IN-6
|
RAD51
|
Cancer
|
|
RAD51-IN-6 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-6 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 23).
|
-
- HY-110078
-
|
Eeyarestatin I
|
p97
Apoptosis
|
Cancer
|
|
Eeyarestatin I, a potent endoplasmic reticulum-associated protein degradation (ERAD) inhibitor, is a potent protein translocation inhibitor. Eeyarestatin I inhibits Sec61 translocon. Eeyarestatin I targets the p97-associated deubiquitinating process (PAD) and inhibits atx3-dependent deubiquitination. Eeyarestatin I interferes at a step prior to proteasomal degradation. Eeyarestatin I induces cell death via the proapoptotic protein NOXA and has anticancer effects.
|
-
- HY-147924
-
|
Keap1-Nrf2-IN-11
|
Keap1-Nrf2
NO Synthase
ROS Kinase
|
Inflammation/Immunology
|
|
Keap1-Nrf2-IN-11 (compound 6k) is a Keap1-Nrf2 inhibitor with KD2 value of 0.21 nM. Keap1-Nrf2-IN-11 inhibits the productions of ROS and NO and the expression of TNF-α. Keap1-Nrf2-IN-11 relieves inflammations by increasing the Nrf2 nuclear translocation. Keap1-Nrf2-IN-11 can be used for anti-inflammatory research.
|
-
- HY-123940
-
|
SGC-AAK1-1
|
AAK1
|
Cancer
|
|
SGC-AAK1-1 is a potent and selective AAK1 (AP2 associated kinase 1) inhibitor with an IC50 of 270 nM and a Ki of 9 nM. SGC-AAK1-1 also potently inhibits BMP2K. SGC-AAK1-1 is used to study Wnt pathway related to AAK1.
|
-
- HY-P1174
-
-
- HY-149037
-
|
GL67
N4-Spermine cholesteryl carbamate
|
Others
|
Others
|
|
GL67 (N4-Spermine cholesteryl carbamate) is a cationic lipid. GL67 can be used for nucleic acid agents and vaccines delivery, and gene transfection.
|
-
- HY-143735
-
|
RAD51-IN-4
|
RAD51
|
Cancer
|
|
RAD51-IN-4 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-4 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2019014315A1, compound R12).
|
-
- HY-D1537
-
|
Dibenzocyclooctyne-Cy5.5
DBCO-Cy5.5; Cyanine5.5 DBCO
|
Fluorescent Dye
|
Others
|
|
Dibenzocyclooctyne-Cy5.5 (DBCO-Cy5.5) is a fluorescent dye. Dibenzocyclooctyne-Cy5.5 can be used to syntheses calcium-binding near-infrared fluorescent nanoprobe for bone tissue imaging.
|
-
- HY-119374
-
|
BRM/BRG1 ATP Inhibitor-1
|
Epigenetic Reader Domain
|
Cancer
|
|
BRM/BRG1 ATP Inhibitor-1 (compound 14) is an orally active allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM. BRM/BRG1 ATP Inhibitor-1 has anticancer activity.
|
-
- HY-149037A
-
|
GL67 pentahydrochloride
N4-Spermine cholesteryl carbamate pentahydrochloride
|
Others
|
Others
|
|
GL67 (N4-Spermine cholesteryl carbamate) (pentahydrochloride) is a cationic lipid. GL67 can be used for nucleic acid agents and vaccines delivery, and gene transfection.
|
-
- HY-131994
-
|
STING agonist-16
|
STING
|
Cancer
Infection
|
STING agonist-16 (1a) is a specific stimulator of interferon genes (STING) agonist. STING agonist-16 (1a) can be used as a potential antiviral and antitumor tool.
|
-
- HY-111752
-
-
- HY-119695B
-
-
- HY-119695A
-
-
- HY-119695
-
-
- HY-115292
-
-
- HY-147741
-
|
DPPY
|
JAK
Btk
EGFR
|
Cancer
Inflammation/Immunology
|
|
DPPY (compound 6) is a potent PTK inhibitor with IC50 values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF).
|
-
- HY-12651
-
|
Primaquine diphosphate
Primaquine phosphate; Primaquine bisphosphate
|
Parasite
|
Infection
|
|
Primaquine Diphosphate (Primaquine phosphate), an 8-aminoquinoline, exerts a broad spectrum of activities against various stages of parasitic malaria. Primaquine Diphosphate remains as the only agent that destroys late hepatic stages and latent tissue forms of Plasmodium vivax and Plasmodium ovale.
|
-
- HY-121982
-
|
Cyclo(L-Phe-L-Val)
|
Fungal
|
Infection
|
|
Cyclo(L-Phe-L-Val) is a potent inhibitor of enzymes isocitrate lyase (ICL) (IC50=27 μg/mL). cyclo(L-Phe-L-Val) inhibits the gene transcription of ICL in C. albicans under C2-carbon-utilizing conditions.
|
-
- HY-148281
-
|
TMX-2164
|
Bcl-2 Family
|
Cancer
|
|
TMX-2164 is a potent, irreversible B-cell lymphoma 6 (BCL6) inhibitor with an IC50 value of 152 nM. TMX-2164 displays sustained target engagement and antiproliferative activity in cells.
|
-
- HY-N0866
-
|
20-Deoxyingenol
|
Autophagy
|
Inflammation/Immunology
|
|
20-Deoxyingenol, a diterpene, is isolated from the roots of Euphorbia kansui. 20-Deoxyingenol can promote autophagy and lysosomal biogenesis by promoting the nuclear translocation of transcription factor EB (TFEB) in vitro. 20-Deoxyingenol can be used for the research of osteoarthritis (OA).
|
-
- HY-134039
-
|
5-Hydroxy-8-methoxypsoralen
5-Hydroxyxanthotoxin
|
Others
|
Inflammation/Immunology
|
|
5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite of Xanthotoxin. Xanthotoxin is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight.
|
-
- HY-146408
-
|
ALK-IN-21
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
ALK-IN-21 (Compound B10), a potent ALK inhibitor for ALKG1202R mutation, exhibits remarkable enzymatic inhibitory potency with IC50 values of 4.59 nM, 2.07 nM and 5.95 nM toward ALK WT, ALK L1196M and ALK G1202R, respectively. ALK-IN-21 efficiently inhibits the proliferation of ALK-positive Karpas299 and H2228 cells both with IC50 values of 0.07 μM. ALK-IN-21 can be used for the research of anaplastic large cell lymphoma.
|
-
- HY-13582
-
|
Carbendazim
|
Fungal
Parasite
|
Infection
Cancer
|
|
Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina. Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma.
|
-
- HY-113919
-
|
Nothofagin
|
Calcium Channel
|
Inflammation/Immunology
|
|
Nothofagin, a dihydrochalcone, is isolated from rooibos (Aspalathus linearis). Nothofagin downregulates NF-κB translocation through blocking calcium influx. Nothofagin has antioxidant activity and ameliorates various inflammatory responses such as the septic response and vascular inflammation.
|
-
- HY-144293
-
|
HDAC-IN-31
|
Apoptosis
HDAC
|
Cancer
|
|
HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma.
|
-
- HY-101559
-
|
10-Nitrooleic acid
CXA-10
|
Others
|
Inflammation/Immunology
|
|
10-Nitrooleic acid (CXA-10), a nitro fatty acid, has potential effects in disease states in which oxidative stress, inflammation, fibrosis, and/or direct tissue toxicity play significant roles.
|
-
- HY-150594
-
|
IRAK4-IN-17
|
IRAK
NF-κB
|
Cancer
|
|
IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM. IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research.
|
-
- HY-32736
-
|
Triptonide
NSC 165677; PG 492
|
Wnt
β-catenin
Apoptosis
Autophagy
|
Cancer
Inflammation/Immunology
|
|
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC50 of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects.
|
-
- HY-13570A
-
-
- HY-13570
-
-
- HY-109109
-
|
Alteminostat
CKD-581
|
HDAC
Apoptosis
|
Cancer
|
|
Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.
|
-
- HY-P99833
-
|
Cosibelimab
CK-301; TG-1501
|
PD-1/PD-L1
|
Cancer
|
|
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells.
|
-
- HY-136373
-
|
Metazachlor
|
Others
|
Others
|
|
Metazachlor is a herbicide of the chloroacetamide class. Metazachlor is an inhibitor of the synthesis of long chain fatty acids and has an effect on cell division or tissue differentiation in the germinating and emerging weed target species.
|
-
- HY-13731
-
|
PPI-2458
|
Others
|
Cancer
Inflammation/Immunology
|
|
PPI-2458 is a potent, orally active, selective and irreversible inhibitor of methionine aminopeptidase-2 (MetAP-2). PPI-2458 can be used for arthritis and lymphoma research.
|
-
- HY-10293
-
|
Aderbasib
INCB007839; INCB7839
|
MMP
|
Cancer
|
|
Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 + breast cancer, gliomas, et al.
|
-
- HY-111753
-
|
WDR5-IN-4
|
Histone Methyltransferase
|
Cancer
|
|
WDR5-IN-4 is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity.
|
-
- HY-P99288
-
|
FG-3019
Pamrevlumab; Anti-Human CTGF Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).
|
-
- HY-13732
-
-
- HY-151807
-
|
15-PGDH-IN-1
|
15-PGDH
|
Metabolic Disease
|
|
15-PGDH-IN-1 is a potent and orally active 15-PGDH inhibitior. 15-PGDH-IN-1 has inhibition activity against recombinant human 15-PGDH with an IC50 value of 3 nM. 15-PGDH-IN-1 can be used for the research of tissue repair and regeneration.
|
-
- HY-125636
-
|
Mycro1
|
Others
|
Cancer
|
|
Mycro1 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC50 value of 30 μM for the inhibition of Myc/Max DNA binding activity. Mycro1 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation.
|
-
- HY-126979
-
|
Mycro2
|
Others
|
Cancer
|
|
Mycro2 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC50 value of 23 μM for the inhibition of Myc/Max DNA binding activity. Mycro2 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation.
|
-
- HY-W010031
-
-
- HY-151808
-
|
JS25
|
Btk
|
Cancer
|
|
JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier.
|
-
- HY-109585
-
|
IRAK4-IN-7
|
IRAK
|
Cancer
Inflammation/Immunology
|
|
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment.
|
-
- HY-114402
-
|
ARD-69
|
Androgen Receptor
PROTACs
|
Cancer
|
|
ARD-69 (compound 34) is a potent PROTAC androgen receptor degrader. ARD-69 induces degradation of androgen receptor (AR) protein in AR-positive prostate cancer cell lines. ARD-69 suppresses AR-regulated gene expression.
|
-
- HY-107413
-
|
SR11237
BMS-649
|
RAR/RXR
|
Cancer
|
|
SR11237 (BMS-649) is a potent retinoid X receptor (RXR)-selective agonist that is devoid of any RAR activity. SR11237 can cause RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.
|
-
- HY-101508
-
|
GNA002
|
Histone Methyltransferase
|
Cancer
|
|
GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC50 of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes.
|
-
- HY-W011138
-
-
- HY-111753A
-
|
WDR5-IN-4 TFA
|
Histone Methyltransferase
|
Cancer
|
|
WDR5-IN-4 TFA is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 TFA displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity.
|
-
- HY-W006566
-
|
5-AIQ
5-Aminoisoquinolin-1-one
|
PARP
|
Cancer
|
|
5-AIQ (5-Aminoisoquinolin-1-one) is a water-soluble PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver.
|
-
- HY-P99230
-
|
Pinatuzumab
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL).
|
-
- HY-30267
-
|
4-Hydroxyphenyl acetate
4-HPA; 4-Acetoxyphenol
|
Endogenous Metabolite
|
Others
|
|
4-Hydroxyphenyl acetate (4-HPA) is a natural antioxidant and protects cells from oxidative stress-induced necrosis. 4-Hydroxyphenyl acetate blocks the increase of cellular ROS induced by oxidative stress, and up-regulates NQO1 and HO-1 genes by stabilizing and inducing the nuclear translocation of NRF2 transcription factor.
|
-
- HY-D1275
-
|
CAY10731
|
Fluorescent Dye
|
Others
|
|
CAY10731 (compound 3) is a highly selective fluorescent probe for detection of hydrogen sulfide (H2S). CAY10731 is used to monitor exo- and endogenous H2S in both cancer and normal cells. CAY10731 is applied for imaging of H2S in living tissues at variable depths and in nematodes.
|
-
- HY-18772
-
|
O4I2
|
Oct3/4
|
Others
|
|
O4I2 is a potent Oct3/4 inducer. O4I2 induces the expression of pluripotent-associated genes Lin28, Sox2 and Nanog, and suppresses Rex1.
|
-
- HY-B0271
-
|
Pyrazinamide
Pyrazinecarboxamide; Pyrazinoic acid amide
|
Bacterial
Autophagy
Antibiotic
|
Infection
|
|
Pyrazinamide?(Pyrazinecarboxamide; Pyrazinoic acid amide) is a potent and orally active antitubercular antibiotic. Pyrazinamide is a proagent that is converted to the active form pyrazinoic acid (POA) by PZase/nicotinamidase encoded by the?pncA?gene in?M. tuberculosis.
|
-
- HY-P99224
-
|
Veltuzumab
IMMU-106; hA20
|
Integrin
|
Cancer
|
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).
|
-
- HY-149833
-
|
ERRγ agonist-2
|
Estrogen Receptor/ERR
|
Infection
Metabolic Disease
|
|
ERRγ agonist-2 is a potent and selective ERRγ inverse agonist with a Kd value of 6.5 μM. ERRγ agonist-2 inhibits the expression of hepcidin, fibrinogen and gluconeogenic genes. ERRγ agonist-2 has antimicrobial, anti-coagulant and antidiabetic activities.
|
-
- HY-100507
-
-
- HY-132300
-
|
ZW4864
|
β-catenin
|
Cancer
|
|
ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM.
|
-
- HY-148717
-
|
NSC363998 free base
|
Others
|
Neurological Disease
|
|
NSC363998 (free base) is an orally active compound. NSC363998 (free base) can suppress rCGG90 induced neurotoxicity. NSC363998 (free base) can be used for the research of neurodegenerative disorder such as Fragile X associated tremor/ataxia syndrome (FXTAS).
|
-
- HY-P1821
-
|
Myelin Basic Protein
MHP4-14
|
PKC
|
Neurological Disease
|
|
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts.
|
-
- HY-P1985A
-
|
Notch 1 TFA
|
Notch
|
Cancer
Cardiovascular Disease
|
|
Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types.
|
-
- HY-146027
-
|
Androgen receptor antagonist 4
|
Androgen Receptor
|
Cancer
|
|
Androgen receptor antagonist 4 (Compound AT2) is an androgen receptor (AR) antagonist with an IC50 of 0.15 μM. Androgen receptor antagonist 4 efficiently antagonizes AR transcriptional activity, suppresses downstream target gene of AR, and blocks the DHT-induced AR nuclear translocation. Androgen receptor antagonist 4 shows anticancer activities.
|
-
- HY-146497
-
|
Topoisomerase I inhibitor 7
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 7 (Compound 8) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 7 significantly inhibits tumor growth (up to 79%) and increases the lifespan (153%) of mice bearing P388 lymphoma transplants. Topoisomerase I inhibitor 7 indicates prospects for further search of new antitumor agent candidates among the heteroarene-fused anthraquinones.
|
-
- HY-149010
-
|
NXPZ-2
|
Keap1-Nrf2
|
Neurological Disease
|
|
NXPZ-2 is an orally active Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with a Ki value of 95 nM, EC50 value of 120 and 170 nM. NXPZ-2 can dose-dependently ameliorate Aβ[1-42]-Induced cognitive dysfunction, improve brain tissue pathological changes in Alzheimer’s disease (AD) mouse by increasing neuron quantity and function. NXPZ-2 can inhibit oxidative stress by increasing Nrf2 expression levels and promoting its cytoplasm to nuclear translocation, which is helpful for Keap1-Nrf2 PPI inhibitors and AD associated disease research.
|
-
- HY-145312
-
|
ATR-IN-4
|
ATM/ATR
|
Cancer
|
|
ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC50s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13).
|
-
- HY-P1821A
-
|
Myelin Basic Protein TFA
MHP4-14 TFA
|
PKC
|
Neurological Disease
|
|
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts.
|
-
- HY-N8376
-
|
Fustin
(±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone
|
Amyloid-β
mAChR
Cholinesterase (ChE)
|
Neurological Disease
|
|
Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research.
|
-
- HY-106449
-
|
Recoflavone
DA-6034 free acid
|
Others
|
Cancer
Inflammation/Immunology
|
|
Recoflavone is a synthetic derivative of eupatilin that has a protective effect on gastric mucosa. Recoflavone has the potential to be used to research peptic ulcer disease.
|
-
- HY-149164
-
-
- HY-15847
-
|
HS38
|
DAPK
|
Cardiovascular Disease
|
|
HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with Kds of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders.
|
-
- HY-132300A
-
|
ZW4864 free base
|
β-catenin
|
Cancer
|
|
ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 (free base) inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM.
|
-
- HY-151264
-
|
BSP16
|
STING
|
Cancer
|
|
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 can selectively stimulate the STING pathway. BSP16 can be used for the research of cancer.
|
-
- HY-P2289
-
|
pBD-1
|
Bacterial
|
Infection
|
|
pBD-1 is an endogenous and constitutively expressed antimicrobial peptide (AMP) from porcine tissues, particularly expresses in pig mucosal epithelial sites. pBD-1 has antimicrobial activities and contributes to mucosal and systemic host defenses in pigs.
|
-
- HY-P3103
-
|
PINT-87aa
|
DNA/RNA Synthesis
|
Cancer
|
|
PINT-87aa, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa suppresses glioblastoma cell proliferation in vitro and in vivo.
|
-
- HY-14171
-
|
Bexarotene
LGD1069
|
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM). Bexarotene can be used for the research of cutaneous T-cell lymphoma.
|
-
- HY-116003
-
|
12,13-DiHOME
|
Endogenous Metabolite
|
Metabolic Disease
|
|
12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders.
|
-
- HY-W048479
-
-
- HY-W048492
-
-
- HY-W048480
-
-
- HY-147374
-
-
- HY-P2289A
-
|
pBD-1 TFA
|
Bacterial
|
Infection
|
|
pBD-1 TFA is an endogenous and constitutively expressed antimicrobial peptide (AMP) from porcine tissues, particularly expresses in pig mucosal epithelial sites. pBD-1 TFA has antimicrobial activities and contributes to mucosal and systemic host defenses in pigs.
|
-
- HY-139104
-
|
Thailanstatin D
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis.
|
-
- HY-147106
-
-
- HY-P3103A
-
|
PINT-87aa TFA
|
DNA/RNA Synthesis
|
Cancer
|
|
PINT-87aa TFA, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa TFA directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa TFA suppresses glioblastoma cell proliferation in vitro and in vivo.
|
-
- HY-136342
-
|
Antitumor agent-23
|
Others
|
Cancer
|
|
Antitumor agent-23 is a potent anti-cancer agent with GI50s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity.
|
-
- HY-12908
-
|
Bcl-xL antagonist 2
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
|
-
- HY-112758
-
|
DLin-KC2-DMA
|
Liposome
|
Others
|
|
DLin-KC2-DMA is an ionisable cationic lipid (pKa≈6) that is virtually non-toxic to antigen presenting cells (APCs). DLin-KC2-DMA produces significant siRNA-mediated gene silencing of GAPDH, when binds to lipid nanoparticles (LNP). DLin-KC2-DMA can be used in siRNA delivery studies.
|
-
- HY-131334
-
|
AMPK activator 4
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect.
|
-
- HY-101082
-
-
- HY-12422
-
|
Voruciclib
|
CDK
|
Cancer
|
|
Voruciclib is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL).
|
-
- HY-12422A
-
|
Voruciclib hydrochloride
|
CDK
|
Cancer
|
|
Voruciclib hydrochloride is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL).
|
-
- HY-125858
-
|
MI-1061
|
MDM-2/p53
E1/E2/E3 Enzyme
Apoptosis
|
Cancer
|
|
MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.
|
-
- HY-W107024
-
|
BMS-986260
|
TGF-β Receptor
|
Cancer
Inflammation/Immunology
|
|
BMS-986260, an immuno-oncology agent, is a potent, selective, and orally active TGFβR1 inhibitor (IC50=1.6 nM). BMS-986260 displays exquisite selectivity for TGFβR1 over its isozyme TGFβR2, as well as in a panel of more than 200 kinases examined. BMS-986260 inhibits TGFβ mediated nuclear translocation of pSMAD2/3 in MINK and NHLF cells lines with an IC50 of 350 nM and 190 nM, respectively.
|
-
- HY-134783
-
-
- HY-132143
-
-
- HY-132147
-
-
- HY-132148
-
-
- HY-132144
-
-
- HY-W048476
-
-
- HY-12649
-
|
Y16
|
Ras
|
Cancer
|
|
Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP.
|
-
- HY-125858A
-
|
MI-1061 TFA
|
MDM-2/p53
E1/E2/E3 Enzyme
Apoptosis
|
Cancer
|
|
MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.
|
-
- HY-145909
-
|
BRD4 Inhibitor-17
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-17 (Compound 5i) is a potent inhibitor of BRD4 with an IC50 of 0.33 μM. BRD4 Inhibitor-17 plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. BRD4 Inhibitor-17 serves as potential antidotes for arsenicals.
|
-
- HY-P99656
-
|
Iladatuzumab
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
|
-
- HY-132292
-
|
ARD-2128
|
PROTACs
Androgen Receptor
|
Cancer
|
|
ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
|
-
- HY-115944
-
|
BTK-IN-9
|
Btk
Apoptosis
|
Cancer
Inflammation/Immunology
|
|
BTK-IN-9 is a reversible BTK inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells. BTK-IN-9 also induces cell apoptosis in Z138 cells.
|
-
- HY-103397
-
|
Nanaomycin A
|
DNA Methyltransferase
Parasite
|
Cancer
Infection
|
|
Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells. Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM.
|
-
- HY-106934A
-
|
Peldesine dihydrochloride
BCX 34 dihydrochloride
|
Nucleoside Antimetabolite/Analog
HIV
|
Cancer
Infection
Inflammation/Immunology
|
|
Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research.
|
-
- HY-101290A
-
|
BMT-090605 hydrochloride
|
Cyclin G-associated Kinase (GAK)
AAK1
|
Neurological Disease
|
|
BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain.
|
-
- HY-101290
-
|
BMT-090605
|
AAK1
Cyclin G-associated Kinase (GAK)
|
Neurological Disease
|
|
BMT-090605 is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 can be used for the research of neuropathic pain.
|
-
- HY-122246
-
-
- HY-15035
-
|
S-Diclofenac
ACS 15; ATB-337
|
COX
|
Inflammation/Immunology
|
|
S-Diclofenac is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac spares the gastric mucosa of injury despite markedly suppressing prostaglandin synthesis.
|
-
- HY-117113
-
|
JI051
|
Notch
|
Cancer
|
|
JI051 is a stabilizer for the Hes1-PHB2 interaction. JI051 interacts with a cancer-associated protein chaperone prohibitin 2 (PHB2), induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1. Anti-cancer activity.
|
-
- HY-Y1620
-
-
- HY-112821
-
|
IBS008738
|
Others
|
Inflammation/Immunology
|
|
IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model.
|
-
- HY-106934
-
|
Peldesine
BCX 34
|
Nucleoside Antimetabolite/Analog
HIV
|
Cancer
Infection
Inflammation/Immunology
|
|
Peldesine (BCX 34) is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research.
|
-
- HY-100365
-
|
Remetinostat
SHP-141
|
HDAC
|
Cancer
|
|
Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma.
|
-
- HY-129966
-
|
PROTAC IRAK4 degrader-1
|
PROTACs
IRAK
|
Cancer
|
|
PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively.
|
-
- HY-107408
-
|
SANT 2
|
Hedgehog
|
Cancer
|
|
SANT 2 is a potent antagonist of Hh-signaling pathway. Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers.
|
-
- HY-P99033
-
|
Mosunetuzumab
BTCT-4465A
|
CD20
|
Cancer
Inflammation/Immunology
|
|
Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).
|
-
- HY-N7038A
-
-
- HY-P0151
-
-
- HY-134922
-
|
NS1-IN-1
|
Influenza Virus
|
Infection
|
|
NS1-IN-1 (compound 3) is a potent NS1 inhibitor. NS1 is a major influenza A virus virulence factor that inhibits host gene expression. NS1-IN-1 decreases viral protein levels, contributing to the reduction of virus replication. NS1-IN-1 shows antiviral activity by repressing the activity of mTORC1 in a TSC1-TSC2-dependent manner.
|
-
- HY-145973
-
|
3'Ome-m7GpppAmpG
|
DNA/RNA Synthesis
|
Others
|
|
3'Ome-m7GpppAmpG is a trinucleotide Cap analogue containing a locked nucleic acid (LNA) molecule. 3'Ome-m7GpppAmpG shows a significant translational efficiency. 3'Ome-m7GpppAmpG can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization.
|
-
- HY-147670
-
|
TPB15
|
Hedgehog
Smo
Gli
Apoptosis
|
Cancer
|
|
TPB15 is an orally active and potent Hh (Hedgehog) signaling inhibitor. TPB15 markedly induces cell cycle arrest and apoptosis in MDA-MB-468 cells. TPB15 blocks Smo (Smoothened) translocation into the cilia and reduced Smo protein and mRNA expression. TPB15 inhibits the expression of the downstream regulatory factor glioma-associated oncogene 1 (Gli1). TPB15 shows good anti-tumor activity with low toxicity.
|
-
- HY-P1928
-
|
Humanin
|
Bcl-2 Family
|
Endocrinology
Neurological Disease
|
Humanin, an anti-apoptotic peptide of 24 amino acids, is a Bax inhibitor. Humanin prevents the translocation of Bax from cytosol to mitochondria, blocks Bax from the inactive to active conformation. Humanin is a mitochondria-associated peptide with a neuroprotective effect against AD-related neurotoxicity. Humanin also improves overall insulin sensitivity in animal. Humanin are related to aging.
Humanin analogue, in which the serine at position 14 is replaced by glycine, names HNG.
|
-
- HY-P99688
-
|
Latozinemab
AL001
|
Neurotensin Receptor
|
Cancer
|
|
Latozinemab (AL001) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research.
|
-
- HY-132588
-
|
Lumasiran
ALN-G01
|
Small Interfering RNA (siRNA)
|
Metabolic Disease
|
|
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
|
-
- HY-115579
-
|
MALAT1-IN-1
|
Others
|
Cancer
|
|
MALAT1-IN-1 (compounds 5) is a potent and specific Malat1 (Metastasis-associated lung adenocarcinoma transcript 1) inhibitor. MALAT1-IN-1 modulated Malat1 downstream genes in a dose-dependent manner without affecting expression of nuclear enriched abundant transcript 1 (Neat1) [1].
|
-
- HY-N2118
-
|
Bilobetin
|
PPAR
PKA
|
Metabolic Disease
|
|
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
|
-
- HY-W048478
-
-
- HY-131340
-
|
LASSBio-1632
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion.
|
-
- HY-105099
-
|
Rifalazil
KRM-1648; ABI-1648
|
DNA/RNA Synthesis
Bacterial
|
Infection
Inflammation/Immunology
|
|
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB).
|
-
- HY-N10661
-
|
Ipomoeassin F
Ipom-F
|
SARS-CoV
|
Cancer
Infection
|
|
Ipomoeassin F is a potent and selective endoplasmic reticulum (ER) protein-translocation inhibitor by targeting the pore-forming subunit of the Sec61 complex (Sec61α) at the ER membrane. Ipomoeassin F selectively inhibits the ER membrane translocation of SARS-CoV-2 proteins. Ipomoeassin F block the ER translocation of secretory proteins and type I transmembrane proteins (TMPs), but not type III TMPs.
|
-
- HY-16214
-
|
FX-11
LDHA Inhibitor FX11
|
Lactate Dehydrogenase
Pyruvate Kinase
Apoptosis
Reactive Oxygen Species
|
Cancer
|
|
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) specific inhibitor, with a Ki of 8 μM. FX-11 can effectively activate PKM2 (pyruvate kinase M2). FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts.
|
-
- HY-130253
-
|
IRAK4-IN-6
|
IRAK
|
Cancer
|
|
IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.
|
-
- HY-18667
-
-
- HY-125209A
-
|
TH5427 hydrochloride
|
DNA/RNA Synthesis
|
Cancer
|
|
TH5427 hydrochloride is a potent, selective NUDT5 inhibitor (IC50=29 nM). TH5427 hydrochloride shows an apparent 690-fold selectivity for NUDT5 over MTH1. TH5427 hydrochloride blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells.
|
-
- HY-103694
-
|
Nebularine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Nebularine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-113431
-
|
Arabinosylhypoxanthine
Hypoxanthine, 9-beta-D-arabinofuranosyl-
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Arabinosylhypoxanthine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152995
-
|
Confidential
|
Others
|
Others
|
|
Confidential is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154269
-
|
Confiden
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confiden is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154270
-
|
Confident
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confident is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-124092
-
|
Raluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Raluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-144126
-
|
S1P1 agonist 5
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS).
|
-
- HY-103017A
-
|
JH-X-119-01
|
IRAK
|
Cancer
Infection
Inflammation/Immunology
|
|
JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice. JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM.
|
-
- HY-152089
-
-
- HY-139995
-
|
Spermine Prodrug-1
|
Others
|
Others
|
|
Spermine precursor-1 (Compound 1) is a redox-sensitive spermine precursor for the potential research of snyder robinson syndrome. Spermine precursor-1 inhibits wild-type (CMS-24949) and spermine synthase gene (SMS) mutant (CMS-26559, and CMS-6233) fibroblast cells with IC50s of 326.7, 198.5, and 244.1 μM, respectively.
|
-
- HY-141431
-
|
Cbl-b-IN-2
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
Inflammation/Immunology
|
|
Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent.
|
-
- HY-154668
-
|
5'-Homocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'- Homocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W007791
-
|
Chloropurine riboside
6-Chloropurine riboside
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Chloropurine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-109108A
-
|
Valemetostat tosylate
DS-3201 tosylate
|
Histone Methyltransferase
|
Cancer
|
|
Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma.
|
-
- HY-149246
-
|
Aβ-IN-6
|
Amyloid-β
Keap1-Nrf2
|
Inflammation/Immunology
Neurological Disease
|
|
Aβ-IN-6 reduces pro-inflammatory cytokine release from microglia cells. Aβ-IN-6 significantly induces Nrf2 nuclear translocation and hamperes Aβ oligomers formation. Aβ-IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. Aβ-IN-6 is an orally active and has antiinflammatory, Antioxidant and Anti-oligomeric activity. Aβ-IN-6 has the potential for Alzheimer's disease (AD) research.
|
-
- HY-152599
-
|
4’-Methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154698
-
|
5’-Homouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Homouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152546
-
|
8-Allyloxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Allyloxyguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152654
-
|
4′-Thiocytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4′-Thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-134295
-
|
8-Chloroinosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152617
-
|
4’-Thioinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-Thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154732
-
|
2-Thiopseudouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-112581
-
|
5-Methoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152462
-
|
8-Azaguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Azaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W602640
-
|
2'-Deoxyisoguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxyisoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152296
-
|
8-Methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W011079
-
|
5-Iodouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154242
-
|
8-Methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152643
-
|
6-Methylpseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154535
-
|
Alpha-inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154329
-
|
2-Deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W244398
-
|
2-Thiocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154253
-
|
α-Azidothymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
α-Azidothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W587829
-
|
4-Thiothymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152615
-
|
4’-Methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-131795
-
|
2-Methylthioadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methylthioadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W576440
-
|
α-Cytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
α-Cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152383
-
|
5-Difluoromethyluridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Difluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152682
-
|
5-Ethyluridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Ethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152368
-
|
8-Hydrazinoadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Hydrazinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-134294
-
|
8-Chloroguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloroguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154536
-
|
Alpha-Guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-Guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152544
-
|
8-Allylthioguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Allylthioguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152807
-
|
4’-Thioadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Thioadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W609639
-
|
2’-Deoxyisocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxyisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154268
-
|
Confidential-2
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confidential-2 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154670
-
|
5’-Homoadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Homoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154534
-
|
Alpha-Adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-Adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W048500
-
|
2-Thiothymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-151414
-
|
3'-Deoxyinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-Deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-131792
-
|
2-Chloroinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152314
-
|
2-Cyanoadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Cyanoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W100215
-
|
5-Methylcyclocytidine hydrochloride
5-Methylcyclocytidine hydrochlorine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methylcyclocytidine hydrochloride is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152800
-
|
7-Deazaguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154275
-
|
4’-Methylthymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-Methylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152740
-
|
5-Pyrrolidinomethyluridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Pyrrolidinomethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W009163
-
|
5-Bromouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154421
-
|
2’,5’-Dideoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,5’-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-149072
-
|
TLR7 agonist 11
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 11 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-N8525
-
|
3'-O-Acetylthymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-O-Acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-149071
-
|
TLR7 agonist 10
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 10 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152869
-
|
5-(Trifluoromethyl)cytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(Trifluoromethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152656
-
|
2-Hydrazinyl-adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Hydrazinyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152510
-
|
5-(Aminomethyl)uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Aminomethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152794
-
|
7-Methyl wyosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Methyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-105006
-
|
Spongosine
2-Methoxyadenosine; 2-O-Methylisoguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Spongosine (2-Methoxyadenosine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152420
-
|
2-Trifluoromethyl adenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Trifluoromethyl adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154474
-
|
3’,4-Dideoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,4-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W013259
-
-
- HY-152375
-
|
8-Hydroxy-xyloguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-xyloguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152327
-
-
- HY-W154568
-
|
6-Methylpurine riboside
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methylpurine riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-130806
-
|
Dihydrodeoxyuridine
H2dUrd
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Dihydrodeoxyuridine (H2dUrd) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152602
-
|
1,3'-Dimethylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,3'-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152854
-
|
5-(Hydroxymethyl)cytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(Hydroxymethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152441
-
|
2-Aminomethyl adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Aminomethyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152387
-
|
8-Chloro-arabinoadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloro-arabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154131
-
|
3-Deaza-xylouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Deaza-xylouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W014306
-
|
2',3'-Dideoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W020361
-
|
2'-C-Ethynyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-C-Ethynyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-130805
-
|
5-Hydroxyuridine
OHUrd
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Hydroxyuridine (OHUrd) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W412546
-
|
3’-O-Methyluridine
4-[1-[(2-Methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152321
-
|
5-Hydroxy-arabinouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxy-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152586
-
|
2′,3′-Anhydroadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′,3′-Anhydroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152867
-
|
5-(Trifluoromethyl)uridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(Trifluoromethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-P99114
-
|
Sugemalimab
|
PD-1/PD-L1
|
Cancer
|
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.
|
-
- HY-125355
-
|
SEC
|
Apoptosis
|
Cancer
|
|
SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation.
|
-
- HY-154537
-
|
3’-O-Methyl inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154616
-
-
- HY-152474
-
|
2’-β-C-Ethynylcytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Ethynylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154356
-
-
- HY-W556301
-
-
- HY-152313
-
|
2-Bromoadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Bromoadenosine, antimalarial agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W108399
-
-
- HY-154256
-
|
5-(2-Azidoethyl)uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2-Azidoethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152475
-
|
2’-β-C-Ethynyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Ethynyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152594
-
|
Uridine-5-oxyacetic acid
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine-5-oxyacetic acid is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154530
-
|
DMTr-TNA-C(Bz)-amidite
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-TNA-C(Bz)-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152318
-
|
Adenosine-2-carboxamide
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Adenosine-2-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152613
-
|
N2-Ethylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-Ethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152649
-
-
- HY-154620
-
|
2′-O-Hexadecyl-adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-O-Hexadecyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154674
-
|
N1-Allylpseudouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Allylpseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154626
-
|
2’-O-Hexadecanyl guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Hexadecanyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152384
-
|
5’(R)-C-Methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152837
-
|
1,3-Dimethyl pseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,3-Dimethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154109
-
|
N1-Aminopseudouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154528
-
-
- HY-W550365
-
-
- HY-152871
-
-
- HY-154110
-
|
N3-Aminopseudouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154453
-
|
4-Deoxy-xylo-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154187
-
-
- HY-W128112
-
|
1-(a-D-ribofuranosyl)uracil
alpha-D-Ribofuranoside,2,4(1H,3H)-pyrimidinedione-1
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(a-D-ribofuranosyl)uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152454
-
|
4’-α-C-Methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-α-C-Methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-137589
-
|
N6-Dimethyldeoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Dimethyldeoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154398
-
|
5-Aza-xylo-cytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-xylo-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152767
-
|
N1-Ethylpseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Ethylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154621
-
|
3’-O-Hexadecanyl adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Hexadecanyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-146494
-
|
Androgen receptor antagonist 5
|
Androgen Receptor
|
Cancer
|
|
Androgen receptor antagonist 5 (compound 42f) is a potent androgen receptor (AR) antagonist with an IC50 value of 6.17 μM. Androgen receptor antagonist 5 can effectively impair AR nuclear translocation, reducing the levels of nuclear AR, and disrupts AR-mediated gene regulation. Androgen receptor antagonist 5 has antiproliferative activity against LNCaP and exhibits antitumor activity in LNCaP xenograft tumor mice model. Androgen receptor antagonist 5 can be used for researching prostate cancer.
|
-
- HY-N3540
-
|
Caraphenol A
|
Others
|
Inflammation/Immunology
|
|
Caraphenol A is a resveratrol trimer and is able to transiently reduce interferon-induced transmembrane (IFITM) protein expression. Caraphenol A safely enhances lentiviral vector gene delivery to hematopoietic stem and progenitor cells. Caraphenol A also inhibits human cystathionine β-synthase (hCBS) and human cystathionine γ- lyase (hCSE) with IC50s of 5.9 μM and 12.1 μM, respectively.
|
-
- HY-152344
-
|
2’-β-C-Methyl inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152795
-
|
N4-Desmethyl wyosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Desmethyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W130204
-
|
N-Acetyl-2′-deoxycytidine
N4-Acetyl-2'-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-Acetyl-2′-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-131611
-
|
6-Azuridine
6-Azauridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Azuridine (6-Azauridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152609
-
|
N1-Cyanomethyl pseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Cyanomethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154553
-
|
3’,5’-Di-O-acetylthymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152411
-
|
3’-Beta-C-Methyl-inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Beta-C-Methyl-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152323
-
-
- HY-152608
-
|
N6-iso-Propyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-iso-Propyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152814
-
|
2′-β-C-Methyl isoguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-β-C-Methyl isoguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152725
-
|
N1-Benzyl pseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Benzyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154354
-
-
- HY-20142
-
-
- HY-152345
-
-
- HY-152464
-
|
N1-Methyl-arabinoadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-arabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-137848
-
-
- HY-152598
-
|
N1-Methylxylo-guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methylxylo-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154722
-
-
- HY-152417
-
|
N3-Ethyl pseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-Ethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152447
-
|
3’-beta-C-Ethynyl inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152346
-
|
N1-Benzoyl pseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Benzoyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152459
-
-
- HY-152342
-
-
- HY-W009234
-
|
6-Chloroguanineriboside
6-Chloroguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Chloroguanineriboside (6-Chloroguanosine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152625
-
|
2’-Beta-C-Ethynyl inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152385
-
|
5,6-Dihydro-ara-uridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5,6-Dihydro-ara-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-N10623
-
|
5-epi-Arvestonate A
|
Tyrosinase
|
Cancer
|
|
5-epi-Arvestonate A is a sesquiterpenoid isolated from the whole plants of Seriphidium transiliense. 5-epi-Arvestonate A promotes melanogenic production by activating the transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase family genes. 5-epi-Arvestonate A inhibits the expression of IFN-γ-chemokine through the JAK/STAT signaling pathway in immortalized human keratinocyte (HaCaT) cells.
|
-
- HY-145550
-
|
Amredobresib
BI894999
|
Epigenetic Reader Domain
|
Cancer
|
|
Amredobresib is a potent inhibitor of BET. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription. Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer (extracted from patent WO2019145410A1 and WO2021175824A1).
|
-
- HY-77644
-
|
5'-Deoxy-5'-iodouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Deoxy-5'-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154717
-
|
2-Deoxy-2’-fluoroisocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxy-2’-fluoroisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152298
-
|
5-Fluoro-4’-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Fluoro-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152701
-
-
- HY-152743
-
|
8-Aza-7-deazguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-7-deazguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-482934
-
|
2’-Deoxy-2’-fluoroinosine
2'-Fluoro-2'-deoxyinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152622
-
|
3’-Deoxy-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154559
-
-
- HY-152351
-
|
8-Bromo-3’-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154001
-
-
- HY-149220
-
-
- HY-W011168
-
|
8-Bromo-2'-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-2'-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154114
-
|
2′-Deoxy-2-iodoadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-iodoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W013330
-
|
3′-Deoxyguanosine
Guanosine, 3'-deoxy-
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Deoxyguanosine (Guanosine, 3'-deoxy-) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152295
-
|
3’-Deoxy-2’-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-2’-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152334
-
|
2’-Chloro-2’-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Chloro-2’-deoxyadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W141338
-
|
2′-Bromo-2′-deoxyuridine
2'-Bromo-2'-deoxy-D-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Bromo-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-102018
-
|
3'-Deoxy-3'-fluoroadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3'-Deoxy-3'-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154324
-
|
2′-Deoxy-2-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154241
-
|
8-Methyl-2’-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154347
-
|
5′-Deoxy-5′-iodothymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Deoxy-5′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152540
-
|
5-Methoxy-4-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152505
-
|
5-Methyl-4-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152731
-
|
3′-Deoxy-3′-methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-Deoxy-3′-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154491
-
|
5’-Deoxy-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152448
-
|
2’-Azido-2’-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Azido-2’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154011
-
|
8-Amino-2′-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Amino-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152666
-
|
5-Methyl-4’-thiocytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-4’-thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154153
-
|
2-Methyl-2’-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154088
-
|
3′-Deoxy-3′-iodothymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Deoxy-3′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W460267
-
|
N2,2'-O-Dimethylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2,2'-O-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-149160
-
|
5′-Amino-5′-deoxythymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Amino-5′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152367
-
|
8-Hydroxy-3’-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152720
-
|
3’-Azido-3’-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152630
-
|
3’-Deoxy-5-fluorouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152771
-
|
3′-Deoxy-3′-fluorocytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-Deoxy-3′-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154364
-
-
- HY-154327
-
|
DMTr-dH2U-amidite
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-dH2U-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154054
-
|
5′-Azido-5′-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Azido-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154214
-
-
- HY-154025
-
|
8-Azido-2′-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Azido-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154589
-
-
- HY-154520
-
|
2-Chloro-3′-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-3′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154467
-
|
2′-Deoxy-6-thioinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-6-thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154243
-
|
8-Methyl-2’-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methyl-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152445
-
|
3’-Amino-3’-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152354
-
-
- HY-154200
-
|
3’-Deoxy-5-methycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-5-methycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152452
-
|
2′-Amino-2′-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Amino-2′-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152821
-
|
5-Methoxy-4’-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154540
-
|
Alpha-5-Methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-5-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152628
-
|
3’-Deoxy-3-deazauridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3-deazauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152465
-
-
- HY-131802
-
|
3'-Azido-3'-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3'-Azido-3'-deoxyadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154554
-
|
3’,5’-Di-O-benzoyl thymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-benzoyl thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152700
-
|
5-Methoxy-2-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154215
-
-
- HY-152320
-
-
- HY-154087
-
|
3′-Bromo-3′-deoxythymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Bromo-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152519
-
-
- HY-154443
-
|
Rev dC(Bz)-5'-amidite
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev dC(Bz)-5'-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154300
-
-
- HY-154405
-
|
5’-Azido-5’-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W154172
-
|
2′-Chloro-2′-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Chloro-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152533
-
|
5-Ethyl-4-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Ethyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-137600
-
|
1,N6-Ethenoadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Ethenoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152631
-
|
3’-Deoxy-5-methoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154666
-
|
3’-Azido-3’-deoxyinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Azido-3’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154470
-
|
8-Aza-2’-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152591
-
|
4’-Methyl-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152730
-
|
3’-Deoxy-3’-fluoroinosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152728
-
|
3’-Azido-3’-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154740
-
|
3′-Chloro-3′-deoxythymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Chloro-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W039275
-
|
5'-Deoxy-5'-iodoguanosine
5'-Iodo-5'-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Deoxy-5'-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152765
-
|
3′-Deoxy-3′-fluorouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-Deoxy-3′-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W006957
-
|
N6-(2-Hydroxyethyl)adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-(2-Hydroxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152710
-
-
- HY-154692
-
|
2′-Deoxy-5-methylisocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-5-methylisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152440
-
|
3’-Amino-3’-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152793
-
|
7-Cyano-7-deazaguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Cyano-7-deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154294
-
|
N1-Methyl ara-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154120
-
|
6-Aza-2'-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Aza-2'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W251781
-
|
4-Thio-2’-deoxyuridine
2′-Deoxy-4-thiouridine; 4-Thiodeoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Thio-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W013052
-
|
8-Bromo-2'-deoxyadenosine
8-Bromo-9-(2-deoxypentofuranosyl)-9H-purin-6-amine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152739
-
-
- HY-154399
-
|
5-Aza-3’-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152870
-
|
2’-O-(2-Azidoethyl)adenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154232
-
-
- HY-152759
-
-
- HY-154012
-
-
- HY-152308
-
-
- HY-154248
-
|
2’-Deoxy-3’,2-anhydrouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-3’,2-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154147
-
|
2’-Deoxy-N1-methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152659
-
|
N1-Propargylpseudouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Propargylpseudouridine (see GL102032) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154624
-
-
- HY-152737
-
-
- HY-152662
-
-
- HY-154038
-
-
- HY-154392
-
|
2-Chloro-2’-deoxy inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-2’-deoxy inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W392809
-
|
5-Methyl-2′-O-methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-2′-O-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154533
-
|
3’-O-Acetyl-2’-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Acetyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154456
-
-
- HY-154237
-
|
5’-O-DMTr-3’-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154556
-
-
- HY-152548
-
|
4’-C-Methyl-4-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152377
-
|
5-Hydroxy-2’-O-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxy-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152865
-
-
- HY-154697
-
|
3-epi-Azido-3-deoxythymidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-epi-Azido-3-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152640
-
|
5-Fluoro-4’-thio-cytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Fluoro-4’-thio-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154400
-
|
5-Aza-3’-beta-methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-3’-beta-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152707
-
|
2-Amino-2′-C-methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-2′-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154239
-
-
- HY-152593
-
|
3’-Deoxy-N1-methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152379
-
-
- HY-154374
-
-
- HY-W603690
-
-
- HY-W550918
-
|
5-Bromo-2’-O-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromo-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152433
-
-
- HY-152752
-
-
- HY-154333
-
-
- HY-W560803
-
-
- HY-154625
-
-
- HY-152551
-
|
4’-C-Methyl-2-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154569
-
-
- HY-77645
-
|
4',5'-Didehydro-5'-deoxyuridine
1-(5-Deoxy-beta-D-erythro-pent-4-enofuranosyl)uracil
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4',5'-Didehydro-5'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154564
-
-
- HY-152836
-
-
- HY-154289
-
-
- HY-152516
-
-
- HY-154420
-
-
- HY-154026
-
-
- HY-152717
-
|
2’-O-Methyl-2-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152499
-
|
1-Methyl-2'-O-methylinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-Methyl-2'-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154303
-
-
- HY-154204
-
-
- HY-152996
-
-
- HY-154602
-
-
- HY-152868
-
|
3’-O-(2-Azidoethyl)adenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152584
-
-
- HY-152336
-
-
- HY-152590
-
|
3’-Deoxy-N6-methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154372
-
|
2′,5′-Dideoxy-5′-iodouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,5′-Dideoxy-5′-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154496
-
|
2’-Deoxy-N3-methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N3-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154558
-
|
2′-Deoxy-6-O-methylinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-6-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152316
-
-
- HY-152866
-
-
- HY-154052
-
-
- HY-W415119
-
|
2',3'-Di-O-acetyl-D-uridine
acetic acid 4-acetoxy-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydrofuran-3-yl ester
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Di-O-acetyl-D-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152607
-
-
- HY-152307
-
|
2-Chloro-N6-methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154293
-
|
3’-Deoxy-N6-ethyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-ethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-137548
-
-
- HY-154055
-
-
- HY-152577
-
-
- HY-152554
-
-
- HY-154510
-
|
2’-Deoxy-N4-methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N4-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152638
-
|
2-Amino-3’-O-methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-3’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152588
-
|
3’-Deoxy-N1-methyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152325
-
-
- HY-W347492
-
|
6-O-Methyldeoxyguanosine
O6-Methyl-2′-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
O6-Methyldeoxy guanosine; DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152425
-
-
- HY-152513
-
|
2’-O-Methyl-4-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-112582S
-
|
N1-Methylpseudouridine-d3
1-Methylpseudouridine-d3; N1-methyl-pseudouridine-d3
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methylpseudouridine-d3 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-D0076
-
-
- HY-103185
-
|
CCPA
2-Chloro-N6-cyclopentyladenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
CCPA (2-Chloro-N6-cyclopentyladenosine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154544
-
-
- HY-152561
-
|
5’(R)-C-Methyl-2-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W357202
-
|
7’-OH-N-trityl morpholinothymine
PMO Thymidine Precusor
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7’-OH-N-trityl morpholinothymine (PMO Thymidine Precusor) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152397
-
-
- HY-154142
-
-
- HY-152317
-
|
5-Methyl-2-thio-xylo-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methyl-2-thio-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152514
-
-
- HY-154136
-
-
- HY-154201
-
|
3’-Deoxy-O6-methyl inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-O6-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W011725
-
|
N-6-Methyl-2-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N-6-Methyl-2-deoxyadenosine is an adenine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W013728
-
-
- HY-152326
-
|
2’-β-C-Methyl-6-azauridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154568
-
-
- HY-148019
-
-
- HY-154472
-
|
N4-Ethyl-2’-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Ethyl-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154233
-
-
- HY-154428
-
-
- HY-152715
-
|
2’-C-β-Methyl-4-deoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-C-β-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152749
-
-
- HY-154130
-
-
- HY-154292
-
|
3’-Deoxy-N1-Methyl inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154262
-
|
N6-Ethyl-2’-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W570891
-
-
- HY-152635
-
-
- HY-152467
-
-
- HY-152880
-
-
- HY-152592
-
-
- HY-154468
-
-
- HY-154129
-
-
- HY-154348
-
-
- HY-152530
-
-
- HY-154296
-
-
- HY-152729
-
-
- HY-154018
-
|
N4-Benzoyl-5-methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154161
-
-
- HY-152721
-
|
3’-O-Methyl-4-deoxy uridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-O-Methyl-4-deoxy uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152497
-
|
3’-β-C-Methyl-2-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-C-Methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152629
-
-
- HY-152428
-
-
- HY-154600
-
|
N4-Benzoyl-3’-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152768
-
-
- HY-152442
-
-
- HY-152651
-
-
- HY-152745
-
-
- HY-154430
-
-
- HY-W008615
-
|
5-Iodo-cytidine
5-Iodo-D-cytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-cytidine (5-Iodo-D-cytidine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152601
-
-
- HY-W010681A
-
-
- HY-W394419
-
-
- HY-152322
-
-
- HY-154373
-
-
- HY-154138
-
-
- HY-152501
-
|
8-Chloro-2’-O-methyl inosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-O-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152500
-
|
4-Deoxy-3’-β-C-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-3’-β-C-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-49200
-
-
- HY-154141
-
-
- HY-154128
-
-
- HY-154202
-
-
- HY-154495
-
|
N3-Methyl-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W377454
-
-
- HY-152369
-
|
1,N6-Etheno-ara-adenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Etheno-ara-adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154330
-
-
- HY-152863
-
|
N6-Furfuryl-2-aminoadenosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N6-Furfuryl-2-aminoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W048512
-
-
- HY-152741
-
|
2’-β-C-Methyl-2-thiouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154143
-
-
- HY-152644
-
-
- HY-154432
-
|
N1-Methyl-2’-deoxyinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152415
-
-
- HY-152466
-
-
- HY-152343
-
-
- HY-N3062
-
-
- HY-W047393
-
-
- HY-154231
-
-
- HY-154081
-
-
- HY-154457
-
-
- HY-154064
-
-
- HY-152805
-
-
- HY-154198
-
-
- HY-154257
-
-
- HY-154529
-
-
- HY-154406
-
|
2′-Deoxy-N-methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2-methylguanosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154508
-
-
- HY-152650
-
-
- HY-152400
-
-
- HY-152872
-
-
- HY-154261
-
-
- HY-152675
-
-
- HY-152624
-
|
N6-Methyl-4’-thio-adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152508
-
-
- HY-154323
-
-
- HY-154566
-
-
- HY-152339
-
-
- HY-152606
-
-
- HY-154516
-
-
- HY-152621
-
|
N6-Ethyl-4’-thio-adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152413
-
-
- HY-152461
-
-
- HY-154314
-
-
- HY-154458
-
-
- HY-152738
-
-
- HY-152648
-
-
- HY-154481
-
-
- HY-152324
-
-
- HY-154565
-
-
- HY-154395
-
-
- HY-152421
-
-
- HY-154297
-
-
- HY-145791
-
|
Dideoxycytidinene
2′,3′-Didehydro-2′,3′-dideoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Dideoxycytidinene (2′,3′-Didehydro-2′,3′-dideoxycytidine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-W128788
-
|
2’-Deoxy-2’-fluoro-b-D-arabinocytidine
4-amino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrimidin-2(1H)-one
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-b-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152494
-
-
- HY-154082
-
-
- HY-152804
-
-
- HY-144643
-
|
CYP51/HDAC-IN-1
|
Fungal
HDAC
Cytochrome P450
|
Inflammation/Immunology
|
|
CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis.
|
-
- HY-16938
-
|
5'-Methylthioadenosine
5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine
|
Endogenous Metabolite
Apoptosis
Parasite
|
Cancer
Metabolic Disease
|
|
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
|
-
- HY-154417
-
-
- HY-154170
-
-
- HY-152873
-
-
- HY-152747
-
-
- HY-152332
-
-
- HY-154418
-
-
- HY-154595
-
-
- HY-154344
-
-
- HY-W342664
-
-
- HY-154609
-
-
- HY-152754
-
-
- HY-152487
-
-
- HY-152753
-
-
- HY-152760
-
-
- HY-W539754
-
-
- HY-154230
-
-
- HY-152337
-
-
- HY-152708
-
-
- HY-152664
-
-
- HY-152778
-
-
- HY-152353
-
-
- HY-152723
-
-
- HY-152330
-
-
- HY-152302
-
-
- HY-154396
-
-
- HY-152362
-
-
- HY-152802
-
-
- HY-154599
-
-
- HY-152803
-
-
- HY-W010917
-
-
- HY-154288
-
-
- HY-154066
-
-
- HY-W054074
-
-
- HY-154573
-
-
- HY-152761
-
-
- HY-154642
-
-
- HY-152359
-
-
- HY-152335
-
-
- HY-152724
-
-
- HY-152439
-
-
- HY-152645
-
-
- HY-154320
-
-
- HY-154513
-
-
- HY-152713
-
-
- HY-152482
-
-
- HY-152329
-
-
- HY-154156
-
-
- HY-152712
-
-
- HY-152653
-
-
- HY-154578
-
|
N1-Methyl-2’-deoxyadenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxyadenosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152457
-
-
- HY-152757
-
-
- HY-W551974
-
-
- HY-154415
-
-
- HY-154402
-
-
- HY-154213
-
-
- HY-154085
-
-
- HY-W048487
-
|
N6-Benzoyl-7’-OH-morpholino adenine
N6-Benzoyl-7'-OH-Morpholino adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-7’-OH-morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152455
-
-
- HY-152549
-
-
- HY-152693
-
-
- HY-152611
-
-
- HY-152356
-
-
- HY-152306
-
-
- HY-154190
-
-
- HY-154259
-
-
- HY-W113081
-
|
4′-Thiouridine
1-(4-Thio-beta-D-ribofuranosyl)uracil
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4′-Thiouridine (1-(4-thio-beta-D-ribofuranosyl)uracil) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152456
-
-
- HY-152733
-
-
- HY-152688
-
-
- HY-154271
-
|
TLR7 agonist 12
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 12 (example 20) is a TLR7 agonist, also is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154119
-
-
- HY-154346
-
-
- HY-148346
-
-
- HY-P99711
-
|
Loncastuximab
RB4v1.2
|
CD19
|
Cancer
|
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).
|
-
- HY-117265
-
|
Ovothiol C
|
Others
|
Others
|
|
Ovothiol C (Medkoo;Ovothiol C) is a natural product that can be found in eggs or ovarian tissue.
|
-
- HY-154121
-
-
- HY-W397503
-
|
5’-O-DMTr-5-iodo-2’-deoxyuridine
2'-Deoxy-5'-O-DMT-5-iodouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-5-iodo-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154167
-
-
- HY-152566
-
-
- HY-154526
-
-
- HY-149070
-
-
- HY-152813
-
-
- HY-154218
-
-
- HY-152435
-
-
- HY-152509
-
-
- HY-152618
-
-
- HY-152315
-
-
- HY-152424
-
-
- HY-154305
-
-
- HY-152627
-
-
- HY-154545
-
-
- HY-154473
-
-
- HY-152563
-
-
- HY-154291
-
-
- HY-154133
-
-
- HY-154059
-
-
- HY-131818
-
|
5'-Amino-5'-deoxyadenosine
NH2dAdo; Nsc 238990
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Amino-5'-deoxyadenosine (NH2dAdo; Nsc 238990) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152340
-
-
- HY-152507
-
-
- HY-154465
-
-
- HY-154319
-
-
- HY-W017749
-
-
- HY-152633
-
-
- HY-154394
-
-
- HY-152642
-
-
- HY-154407
-
-
- HY-154511
-
-
- HY-154295
-
-
- HY-154159
-
-
- HY-154391
-
-
- HY-131847
-
|
2,6-Dichloro-2',3',5'-triacetyl-purine riboside
2,6-Dichloro-9-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)purine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,6-Dichloro-2',3',5'-triacetyl-purine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-152518
-
-
- HY-152817
-
-
- HY-152301
-
-
- HY-152489
-
-
- HY-154370
-
-
- HY-154308
-
-
- HY-152403
-
-
- HY-152504
-
-
- HY-154579
-
-
- HY-152626
-
-
- HY-154355
-
-
- HY-152444
-
-
- HY-154531
-
-
- HY-154203
-
-
- HY-152815
-
-
- HY-154132
-
-
- HY-154246
-
-
- HY-152311
-
-
- HY-154404
-
-
- HY-154345
-
-
- HY-154134
-
-
- HY-154158
-
-
- HY-154306
-
-
- HY-152390
-
-
- HY-154238
-
-
- HY-P99048
-
|
Sintilimab
IBI308
|
PD-1/PD-L1
|
Cancer
Inflammation/Immunology
|
|
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.
|
-
- HY-154660
-
-
- HY-152585
-
-
- HY-154266
-
-
- HY-152484
-
-
- HY-154205
-
-
- HY-154235
-
-
- HY-154371
-
-
- HY-152486
-
-
- HY-152736
-
-
- HY-152597
-
-
- HY-152481
-
-
- HY-154408
-
-
- HY-41793
-
-
- HY-W457757
-
-
- HY-I0100
-
-
- HY-152634
-
-
- HY-154307
-
-
- HY-W357201
-
|
N4-Benzoyl-7’-OH-N-trityl morpholino cytosine
N-[1-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-7’-OH-N-trityl morpholino cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154050
-
-
- HY-152583
-
-
- HY-154331
-
-
- HY-154343
-
-
- HY-152647
-
-
- HY-152412
-
-
- HY-152352
-
-
- HY-152492
-
-
- HY-152393
-
-
- HY-W555976
-
-
- HY-W564313
-
-
- HY-154557
-
-
- HY-154382
-
-
- HY-W357200
-
|
N6-Benzoyl-7’-OH-N-trityl morpholino adenine
N-[9-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-9H-purin-6-yl]-benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-7’-OH-N-trityl morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154234
-
-
- HY-154376
-
-
- HY-W342904
-
|
2’-O-Methyl-5’-O-DMTr-5-iodouridine
5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-5-iodo-2'-O-methyl-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Methyl-5’-O-DMTr-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154304
-
-
- HY-154429
-
-
- HY-154612
-
-
- HY-152796
-
-
- HY-154258
-
|
Rev 2’-O-MOE-5MeU-5’-amidite
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-5MeU-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
|
-
- HY-154677
-
-
- HY-152595
-
-
- HY-154123
-
-
- HY-154263
-
-
- HY-154567
-
-
- HY-154575
-
-
- HY-154086
-
-
- HY-D1560
-
|
FG 488 DHPE
|
Fluorescent Dye
|
Others
|
|
FG 488 DHPE is a lipid-coupled fluorochrome, has be used as a fluorophore Oregon Green 488. FG 488 DHPE monitors acidification of lipid vesicles with λex/λem=508/534 nm. FG 488 DHPE is also used for Hv1-induced proton translocation quantificatio with λex/λem=508/534 nm as well.
|
-
- HY-P99669
-
|
Iratumumab
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL).
|
-
- HY-P2290
-
|
Beta-defensin 1, pig
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Beta-defensin 1, pig is an antimicrobial peptide found primarily in tongue mucosa of pig. Beta-defensin 1, pig is active against bacteria such as Escherichia coli, Salmonella typhimurium, Listeria monocytogenes, Staphylococcus aureus, Bordetella pertussis and Candida albicans.
|
-
- HY-154437
-
-
- HY-154779
-
-
- HY-152503
-
-
- HY-154360
-
-
- HY-152831
-
-
- HY-152735
-
-
- HY-152706
-
-
- HY-154442
-
-
- HY-154037
-
-
- HY-152571
-
-
- HY-154514
-
-
- HY-154309
-
-
- HY-154667
-
-
- HY-154251
-
-
- HY-154160
-
-
- HY-154605
-
-
- HY-154267
-
